Type your drug name (like Atorvastatin, Sildenafil, etc)
Advertisement
Saxagliptin and MetforminKombiglyze XR
Kombiglyze XR is used to lower blood sugar and treat type 2 diabetes. Kombiglyze XR is less popular than other gliptin/biguanide combinations. There are currently no generic alternatives to Kombiglyze XR.
Check our savings tips for co-pay cards, assistance programs, and other ways to reduce your cost. Kombiglyze XR is not covered by most Medicare and insurance plans.
Prescription Settings
brand
tablet
2.5mg/1000mg
60 tablets
Kombiglyze XR(brand)
tablet
2.5mg/1000mg
60 tablets
Insurance Coverage: Many major insurance plans no longer cover Kombiglyze XR. Learn More
Savings Alert: We've added new, lower prices at most pharmacies for this prescription. Learn More
Saxagliptin and Metformin Images
VIEW ALLKombiglyze XR 2.5mg-1000mg Extended Release Tablet
This medicine is a yellow, oblong tablet imprinted with "2.5/1000" and "4222". and is manufactured by Bristol Myers Squibb Co
VIEW PRICESFor Consumers
For Business
Company
Connect
Copyright ©2018 GoodRx, Inc.
GoodRx is not sponsored by or affiliated with any of the pharmacies identified in its price comparisons. All trademarks, brands, logos and copyright images are property of their respective owners and rights holders and are used solely to represent the products of these rights holders. This information is for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis or treatment. GoodRx is not offering advice, recommending or endorsing any specific prescription drug, pharmacy or other information on the site. GoodRx provides no warranty for any of the pricing data or other information. Please seek medical advice before starting, changing or terminating any medical treatment.
In all states except Tennessee, GoodRx is considered a marketer of prescription discount cards, and is not required to register as a discount card provider. In Tennessee, GoodRx is registered as a Prescription Drug Discount Plan Operator.
